EC
NRIX icon

Euclidean Capital’s Nurix Therapeutics NRIX Stock Holding History

Euclidean Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-154,426
Closed -$4.1M – 13
2021
Q2 		$4.1M Buy
+154,426
New +$4.53M 1.33% 11

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Euclidean Capital's NRIX Position: Q3 2021 in Review

Euclidean Capital sold out of Nurix Therapeutics (NRIX) in Q3 2021, closing a stake of 154,426 shares — an estimated $4.1M sold.

Euclidean Capital first reported a position in NRIX in Q2 2021 and held it in 1 quarter. The position peaked at $4.1M in Q2 2021. 113 funds tracked by Wall St. Rank hold NRIX as of Q3 2021.

  • Euclidean Capital reported no remaining Nurix Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Euclidean Capital sold 154,426 Nurix Therapeutics shares in Q3 2021, an estimated $4.1M.
  • Euclidean Capital first reported a position in Nurix Therapeutics in Q2 2021 and held it in 1 quarter.
  • Euclidean Capital's Nurix Therapeutics position peaked at $4.1M in Q2 2021.
  • 113 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2021.

Based on Euclidean Capital's 13F filing for Q3 2021, filed 15 Nov 2021.